What is Qcdx?
Qcdx operates at the intersection of biotechnology and medical diagnostics, specializing in the early detection of circulating tumor cells (CTCs). The company's proprietary technology facilitates enrichment-free profiling, allowing for the isolation of rare cells through minimally invasive liquid biopsies. This approach provides clinicians and researchers with real-time cancer intelligence, which is essential for optimizing therapeutic strategies and monitoring treatment toxicity. By serving both the clinical oncology market and the pharmaceutical drug discovery pipeline, Qcdx addresses critical gaps in patient care and research efficiency, establishing itself as a key player in the next generation of cancer diagnostics.
How much funding has Qcdx raised?
Qcdx has raised a total of $7M across 2 funding rounds:
Debt
$14K
Other Financing Round
$7M
Debt (2021): $14K with participation from PPP
Other Financing Round (2025): $7M, investors not publicly disclosed
Key Investors in Qcdx
PPP
Public-Private Partnership
Undisclosed Investor
A strategic partner providing capital to facilitate the company's latest major expansion and technological development phase.
What's next for Qcdx?
With the recent infusion of capital, Qcdx is expected to scale its operational capacity and advance its clinical validation programs. The strategic focus will likely shift toward broadening the commercial application of its CTC profiling platform, potentially targeting new therapeutic areas within oncology. As the company transitions into a more mature phase of enterprise-level growth, the integration of its diagnostic solutions into standard clinical workflows will be a primary objective. This trajectory suggests a robust outlook for the firm as it continues to refine its technology to meet the rigorous demands of precision medicine and pharmaceutical research.
See full Qcdx company page
